216 related articles for article (PubMed ID: 16638849)
1. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.
Steinbach D; Schramm A; Eggert A; Onda M; Dawczynski K; Rump A; Pastan I; Wittig S; Pfaffendorf N; Voigt A; Zintl F; Gruhn B
Clin Cancer Res; 2006 Apr; 12(8):2434-41. PubMed ID: 16638849
[TBL] [Abstract][Full Text] [Related]
2. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
3. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.
Steinbach D; Bader P; Willasch A; Bartholomae S; Debatin KM; Zimmermann M; Creutzig U; Reinhardt D; Gruhn B
Clin Cancer Res; 2015 Mar; 21(6):1353-9. PubMed ID: 25501127
[TBL] [Abstract][Full Text] [Related]
5. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia.
Skou AS; Juul-Dam KL; Hansen M; Lausen B; Stratmann S; Holmfeldt L; Aggerholm A; Nyvold CG; Ommen HB; Hasle H
J Mol Diagn; 2021 Dec; 23(12):1787-1799. PubMed ID: 34600138
[TBL] [Abstract][Full Text] [Related]
6. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
7. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J;
Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
11. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
[TBL] [Abstract][Full Text] [Related]
13. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
14. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in acute myeloid leukaemia.
Liu Yin JA
Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
17. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
[TBL] [Abstract][Full Text] [Related]
20. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]